MTOR and cancer: With mTOR deregulation and associated mutations being linked to different types of cancers [2,5] the large number of clinical trials in various phases that include rapalogues (a class of allosteric mTOR inhibitors that are derivatives of rapamycin) and other mTOR-related pharmacological interventions and inhibitors (clinicaltrials.gov) is not surprising.